Arabic Arabic English English French French German German
dark

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film

Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021 If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Two confirmed cases aboard quarantined container ship

Next Post

Nippon Chemiphar Presents Promising Data on Novel Prescription Cough Medicine, Representing Possibly Second New Rx Cough Drug to Enter Market Since 1950s

Related Posts
Total
0
Share